NEW YORK (TheStreet) -- Leerink upgraded Allergan (AGN - Get Report) to "outperform" from "market perform" and set a $184 price target. The firm said the risk/reward is compelling, following a significant pullback in the stock.
The stock closed at $151.92 on Thursday.
Must Read: Warren Buffett's 25 Favorite Stocks
Separately, TheStreet Ratings team rates ALLERGAN INC as a "buy" with a ratings score of A+. TheStreet Ratings Team has this to say about their recommendation:
"We rate ALLERGAN INC (AGN) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, compelling growth in net income and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook."
You can view the full analysis from the report here: AGN Ratings Report